Covalent inhibitors: a rational approach to drug discoveryFandi Sutanto, Alexander Dömlingꝉ, Markella Konstantinidou|RSC Medicinal Chemistry|2020Cited by 375
PROTACs– a game-changing technologyMarkella Konstantinidou, Alexander Dömlingꝉ, Jingyao Li et al.|Expert Opinion on Drug Discovery|2019Cited by 159
Immune Checkpoint PD‐1/PD‐L1: Is There Life Beyond Antibodies?Markella Konstantinidou, Alexander Dömlingꝉ, Tryfon Zarganes‐Tzitzikas et al.|Angewandte Chemie International Edition|2017Cited by 133
Inhibitors of programmed cell death 1 (PD-1): a patent review (2010-2015)Tryfon Zarganes‐Tzitzikas, Alexander Dömlingꝉ, Markella Konstantinidou et al.|Expert Opinion on Therapeutic Patents|2016Cited by 104
The tale of proteolysis targeting chimeras (PROTACs) for Leucine‐Rich Repeat Kinase 2 (LRRK2)Markella Konstantinidou, Alexander Dömlingꝉ, Asmaa Oun et al.|ChemMedChem|2020Cited by 42